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Introduction: In primary, estrogen receptor positive (ER+), HER2- breast cancer
(BC), individual risk of distant recurrence determines if patients are recommended to
undergo either adjuvant endocrine therapy alone or with additional chemotherapy
(CT) to reduce the risk of recurrence. Clinical markers and molecular tests such as
EndoPredict (EP, Sividon Diagnostics) can be used to support decision making for
BC management.
Methods: Using a life-long Markov state transition model, we determined the health
economic impact and incremental cost effectiveness ratios (ICERs) of applying the
EP gene expression test in combination with three clinical guidelines (German-S3
[S3] 2008, NCCN 2007, St.Gallen [SG] 2011) to gain additional prognostic
information in early ER+ HER2- BC patients. No CT or no test (all CT) served as
reference strategies. Information on overall and metastasis-free survival were based
on Austrian Breast & Colorectal Cancer Study Group studies (ABCSG6/8, n = 1619).
Effectiveness was assessed in terms of quality-adjusted life-years (QALYs); a disutility
for CT administration was included. Utilities and unit costs were derived from
published literature. Costs were assessed from the perspective of the German
third-party payer. Costs and effects were discounted by 3%.
Results: The average life-long cost per patient ranged from EUR 25’910 (no CT) to
EUR 35’997 (all CT). Due to imperfect prognostic value and differences in CT use,
the various strategies led to clinical outcomes per patient ranging from 13.11 QALYs
(no CT) to 13.17 QALYs (EP alone), respectively. The most favorable incremental
cost-effectiveness ratio was achieved by applying EP to patients who were classified as
high risk (luminal B) by SG, with EUR69’941/QALY compared to no CT. Compared
to SG alone, the combined strategy with SG/EP would save EUR 3’225 (EUR 33’855
vs. EUR 30’088) and gain 0.005 QALYs per patient on average. The combination of
guidelines with EP remained preferable in deterministic and scenario analyses.
Conclusion: Our model suggests that combining the SG guideline with EP is the
most cost-effective approach in ER+ HER2- BC patients, from the perspective of the
German health care system.
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